Shares of BioNTech (BNTX) moved higher after the Pfizer (PFE) posted the results from a 332 person study evaluating two COVID-19 vaccines — BNT162b1 and BNT162b2. “The data set presented here guided our decision to advance BNT162b2 at the 30-undefined dose level into the Phase 2/3, global safety and efficacy evaluation in participants 18-85 years of age. The primary consideration driving this decision was the milder systemic reactogenicity profile of BNT162b2, particularly in older adults, in the context of comparable antibody responses elicited by both candidate vaccines. Short-lived declines in post-vaccination lymphocyte counts were without evidence of associated clinical impact, were observed across age groups, and likely reflect temporary redistribution of lymphocytes from the bloodstream to lymphoid tissues as a functional response to the immune stimulation of immunization,” Pfizer said. Shares of Pfizer vaccine partner BioNTech are up 2% to $66.92 following the release. ():(https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v1.full.pdf)